SARCOPHAGINE CHELATORS AND COPPER ISOTOPES FOR IMAGING AND THERAPY
|
|
- Emmeline Gillian Adams
- 5 years ago
- Views:
Transcription
1 SEEING IS BELIEVING SARCOPHAGINE CHELATORS AND COPPER ISOTOPES FOR IMAGING AND THERAPY Sydney Vital and STEaM Neuroendocrine Tumour Preceptorship May 2018 Amos Hedt Head of Clinical Development 1
2 CLARITY HIGHLIGHTS 2 Clarity is a leading innovative radiopharmaceutical company Clinical stage radiopharmaceutical company Pipeline of copper-based radiopharmaceutical assets Leading patented technology Building a world class team Collaborations with world leading institutes
3 Positive movement MARKET OVERVIEW 3 The Global Nuclear Medicine Market is poised to grow at a CAGR of around 10.2% over the next decade to reach approximately $11.3 billion by 2025 PET Radio therapeutics By 2021, PET procedure volume is predicted to increase to 11 million per year with sales of $5.0 billion Radiotherapeutics represented 4% of the total nuclear medicine market in By 2030, it is forecast to represent over 50% of the $24 billion nuclear medicine market PET SPECT Market Drivers Lu-177, Cu-67, alpha Theranostics / CDx Peptides/Antibodies Centralised manufacturing I-131, Y-90, In-111 Diagnostics Small molecules Hospital radiopharmacy Negative movement
4 CLARITY S CANCER TECHNOLOGY Clarity uses Copper-64 (Cu-64) for PET imaging and dosimetry. This may enable a tailored dose of Copper-67 (Cu-67) for therapy. 4 Cu-64 Peptide IMAGING PRODUCT (PET) Diagnose Select patients Monitor therapy Cu-67 Delayed Imaging Prospective dosimetry Dose per tumour Rate limiting organs Tailored therapy Peptide THERAPY PRODUCT
5 COPPER ISOTOPES:PERFECT PAIRING 5 There are many advantages of using the Cu-64/Cu-67 pairing Cu-64 - Ideal diagnostic PET isotope - T½ 12.7 hours - Centralised supply - GMP suitable - Imaging over 48hrs - Cyclotron produced Cu-67 - Ideal therapy isotope - T½ 2.6 days - Centralised supply - GMP suitable - LINAC produced - IAC
6 VERSATILITY OF Cu-67 Cu-67 may have benefits in efficacy and versatility in timing of dose due to the shorter half-life Characteristic Shorter half life Higher decay rate Faster decay Less side effects off target Better radiation safety Opportunity Better efficacy in some tumours? Fractionated dosing closer together Paediatrics Patients released earlier Linear Quadratic equation: Cell survival as a function of dose for different dose rates
7 COPPER ISOTOPES 7 Why is Cu-64/Cu-67 coming of age now? Chelator Clarity s proprietary SAR chelators do not leak copper in vivo, which enables Cu-67 therapy and dosimetry calculations Supply Cu-64 is produced on cyclotrons, can be GMP, available weekly in the USA, EU, Australia Cu-67 is made on demand in the USA, can become GMP, and is commercially scalable Industry Dosimetry calculations for Cu-67 enabled by Cu-64 Theranostic imaging limit products toxicity and coming maximise on the efficacy market Dosimetry 2.5 days half-life increasing allows repeat dosing to improve efficacy
8 CENTRALISED RADIOPHARMACY Cu-64 and Cu-67 can be produced under GMP conditions and enable centralised manufacture benefits, making supply of a finished GMP product available to all hospitals and private centers 8 Cu-64 Cyclotrons Regional Radiopharmacy Cu-67 LINACS Shipping finished product (GMP) Hospital Hospital Private Practice Private Practice Radiology (PET) Therapy Centre Patient is injected by a nurse
9 CENTRALISED RADIOPHARMACY Cu-64 and Cu-67 enable regional radiopharmacy distribution. Clarity will ship finished product from a regional centre to all its clinical trial sites. 9 Adelaide St Louis
10 CLARITY S Cu-64/Cu-67 PLATFORM Clarity s platform derives its strength from the SAR-chelator technology and a strong IP position around the technology as well as composition patents 10 Cu-64/Cu-67 THERANOSTICS Cu-64 CDx SARTATE -NETs -Neuroblastoma -Meningioma SAR-PSMA -Prostate SAR-BBN -Breast -Prostate -Ovarian -Glioma -Lung SAR-Discovery -Pan-Cancer -Breast -Glioma -Melanoma -Pre-targeting SAR- PlateView -Unstable Plaque SAR-Fibrosis - Fibrosis World Leading Clinical Investigators and Advisers Regulatory Strategy Quality Management System Intellectual Property Strategy
11 CLARITY S CANCER THERANOSTICS Clarity s pipeline is aimed at tapping into achievable markets that can be better served with radiopharmaceutical technologies 11 THERANOSTICS Preclinical Phase1/2a Phase2b SARTATE NETs/Meningioma NETs PET Imaging NETs Therapy SARTATE KIDS Neuroblastoma PET Imaging Neuroblastoma Therapy SAR-PSMA Prostate Cancer PET Imaging Prostate Cancer Therapy SAR-BBN Prostate/Breast/Ovarian/Glioma/Lung PET Imaging Prostate/Breast/Ovarian/Glioma/Lung Therapy Complete Planned
12 DIAGNOSTICS Clarity s pipeline is aimed at tapping into achievable markets that can be better served with radiopharmaceutical technologies 12 COMPANION DIAGNOSTICS Preclinical Phase 0 (FIH) Phase1/2a Partner/Fund PET Imaging Products Vulnerable Plaque PlateView Belgium grant funded Fibrosis Marker Pulmonary/Hepatic/Cardiac NHMRC grant funded Complete Planned
13 SARTATE SARTATE (Cu-64/Cu-67) is a first-in-class, highly targeted theranostic radiopharmaceutical, which can image, perform prospective dosimetry, and subsequently treat cancers that express somatostatin receptor 2 (SSTR2) 13 Clinical Demand Require a diagnostic tool for prospective dosimetry Industry demand Centralised manufacture of product GMP Products Decrease COGS
14 RATIONALE FOR APPROACH 64 Cu-SARTATE allows for multiple scans out to 24 hrs to calculate the therapeutic window to maximise therapeutic dose whilst minimising toxicity For PRRT most centres used fixed administered activity (7-8 GBq of 177 Lu-DOTAoctreotate (LuTate) and 2-4 GBq of 90 Y-DOTA-octreotate (Ytate) Sink effect means that dose to tumor and normal tissues vary markedly with disease burden and avidity Differential radiation doses impact efficacy and toxicity, especially to susceptible target organs such as the kidneys Current dosing plans mean every patient is either over or under-dosed We need better prospective dosimetry estimation, but single time point scanning such as 68 Ga-DOTA-octreotate does not assist with calculation of clearance kinetics from tumour and kidneys
15 STUDY DESIGN Completed Study 15 Clinical Study Clarity-01 Positron Emission Tomography (PET) Imaging of Patients with Low & Intermediate Grade Neuroendocrine Tumors using 64 Cu- SARTATE : A Single Centre, Open-Label, Non-Randomized, Phase-0 Microdosing Investigation
16 STUDY DESIGN 16 Study Parameters Recruitment 10 Patients with neuroendocrine tumors Primary Objectives safety, biodistribution, and dosimetry Secondary Objectives Dose Investigate the interaction of 64 Cu-SARTATE with malignant tissues 200MBq of activity in a maximum of 20µg of peptide Key Inclusion Criteria Low and Intermediate grade NETs (Ki-67 index <20%), prior positive 68 Ga-DOTATATE PET/CT scan, sufficient life expectancy and renal function Key Exclusion Criteria somatostatin sensitivity, current somatostatin treatment, other serious condition
17 Within 28 days STUDY DESIGN 17 Patient Flowchart 68 Ga-DOTATATE PET/CT Scan - Standard of Care Screening Informed Consent / Screening / Baseline Assessments Day 1 Treatment & Scans PET/CT scans performed at 30 minutes, 1hr (PET only) & 4hrs following SARTATE Day 2 Scan PET/CT scan performed 24hrs* following SARTATE * Note due to clinic schedules planned 24hr scans were performed at 20hrs Day 8 Exit Follow-up safety assessment
18 RESULTS: PATIENT DATA 18 Safety Detailed safety review after Pts 001, 002, 005 No SAEs or significant SARTATE-related adverse events observed in any patients All patients completed the study successfully and exited at Day 8
19 RESULTS: PATIENT DATA 19 Patient 001 Unresectable pancreatic primary being considered for neoadjuvant PRRT with Lutate to shrink the tumour to make it operable Borderline renal function (note retention of signal in the kidneys) High tumour retention and good liver clearance at late timepoint
20 RESULTS: PATIENT DATA 20 Patient 002 Extensive nodal and small volume cardiac metastases High tumour retention and good liver clearance at later time point Progressive renal clearance as the signal from the kidneys diminishes
21 RESULTS: PATIENT DATA 21 Patient 003 Patient had tumour surgically removed previously Suspected recurrence at resection margin in the tail of the pancreas Note high uptake in target lesion at 20 hrs compared to GaTate scan
22 RESULTS: PATIENT DATA 22 Patient 003 continued Suspected recurrence at resection margin in the tail of the pancreas Second lesion identified only on delayed imaging and not on standard of care GaTate scan
23 RESULTS: PATIENT DATA 23 Patient 006 Pancreatic NET Progressive liver clearance enhances visualisation of small hepatic metastases at late time points
24 RESULTS: PATIENT DATA 24 Patient 007 Pancreatic NET Comparison to clinical FDG and GaTate Note improved definition of hepatic metastases in late time point scan
25 RESULTS: PATIENT DATA 25 Patient 009 Pancreatic NET Major impact on definition of small intrahepatic metastases at delayed time point
26 RESULTS: TISSUE CLEARANCE Overall, 64 Cu-SARTATE shows clearance from key organs and high retention in tumours, indicating the promise of a personalised therapeutic 67 Cu-SARTATE PRRT approach Cu-SARTATE cleared significantly from the liver and the kidneys between 60 minutes and 24 hours There was not significant clearance from the spleen between 60 minutes and 24 hours Average 64 Cu-SARTATE retention in each patient s hottest tumour remained very high and did not diminish significantly Hottest lesion to liver ratio increased from 8:1 to 21:1 and this was significant (p < 0.001)
27 DOSIMETRY RESULTS Delayed imaging enables dosimetry calculations over 24 hours Whole body Effective Dose (ED) was estimated to be 7-8 msv for a 200 MBq injection of 64 Cu-SARTATE. This compares favourably with 18 F-FDG where 5-6 msv whole body ED for an injected amount of MBq. Estimate radiation dosimetry for 64 Cu- SARTATE in children and for therapeutic administration of 67 Cu-SARTATE in adults. Lesion based dosimetry to estimate Gy
28 CONCLUSIONS 28 Sarcophagine chelator leads to stable 64 Cu binding in vivo, allowing for accurate clearance kinetics to be calculated There was high retention of 64 Cu-SARTATE in tumour sites, with the signal increasing in intensity in the hottest lesions over 24 hrs The clearance of liver activity enhances lesion definition in this organ with the hottest lesion to liver ratio more than doubling Acceptable radiation dosimetry for diagnostic use (similar to existing clinical modalities) Distribution from centralised GMP radiopharmacy is feasible 64 Cu-SARTATE offers prospective dosimetry and theranostic pair with 67 Cu-SARTATE
29 SARTATE KIDS SARTATE Kids is being developed for the treatment of neuroblastoma, one of the most aggressive childhood cancers 29 Neuroblastoma (NB) is the most common cancer to be diagnosed in the first year of life and accounts for around 13% of paediatric cancer mortality (Maris 2010) 84% of neuroblastomas express SSTR2 (Watanabe et al. 2014) SARTATE Kids could help to minimise side effects of current treatments 68 Ga-DOTATATE AND PRRT WITH 177 Lu-DOTATATE Source: Kong et al 2015
30 SARTATE KIDS SSTRs are expressed in a number of childhood cancers, building potential for successful treatment with SARTATE 30 SSTRs are expressed in high densities in the following childhood cancers: Medulloblastomas NETs Neuroblastomas Ganglioneuromas Ganglioneuroblastomas Hepatocellular carcinoma Astrocytoma Brain stem glioma Delayed Imaging Prospective dosimetry Dose per tumour Rate limiting organs Tailored therapy Nov 2017 Q Phase 1/2a imaging study Peptide THERAPY PRODUCT Q Q Phase 2b imaging study Cu Q Q Phase 1/2a therapeutic study
31 Phase 1 Adults Therapy 31 Clinical Study Clarity-02: Peptide Receptor Radionuclide Therapy of Patients with Meningioma with 67 Cu- SARTATE : A single-centre, open-label, non-randomised, personalised-dose, Phase I-IIa Theranostic Clinical Trial
32 Phase 1 Kids Diagnostic 32 Clinical Study Clarity-03: First-In-Human Phase I Clinical Trial of 64 Cu- SARTATE for Imaging and Dosimetry Estimation in Paediatric Patients with High- Risk Neuroblastoma
33 CLARITY S PARTNERS Clarity has established close relationships with industry thought leaders and gained access to world-class facilities, thus facilitating innovation and constantly honing its capabilities 33 CLARITY IN AU CLARITY IN USA
34 CLARITY SUMMARY 34 Clinical stage company with first product SARTATE in clinical trial development Ideal technology suited to biopharma assets for the theranostic treatment of serious diseases Strong patent position Several patent families with all major markets protected Attractive markets Achievable niche markets or large markets in partnership with pharma companies Effective team managing world class partners and researchers here and around the world Utilises Australia s competitive advantages Regulatory framework, clinical trials, radiopharmaceuticals, R&D tax rebate, foreign exchange
35 CLARITY S CONTACTS 35 DR ALAN TAYLOR Executive Chairman Ph: +61 (0) E: ataylor@claritypharm.com AMOS HEDT Head of Clinical Development Ph: +61 (0) E: ahedt@claritypharm.com DR MATT HARRIS CEO Ph: +61 (0) E: mharris@claritypharm.com
Physical Bases : Which Isotopes?
Physical Bases : Which Isotopes? S. Gnesin Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland 1/53 Theranostic Bruxelles, 2 Octobrer 2017 Theranostic : use of diagnostic
More informationNuclear Medicine in Australia. Shaun Jenkinson
Nuclear Medicine in Australia Shaun Jenkinson Landmark Infrastructure for Australian Science OPAL Research Reactor Australian Synchrotron Camperdown Cyclotron Bragg Institute Centre for Accelerator Science
More informationMETROLOGY TO SUPPORT INNOVATION IN MOLECULAR RADIOTHERAPY. Glenn Flux
METROLOGY TO SUPPORT INNOVATION IN MOLECULAR RADIOTHERAPY Glenn Flux Head of Radioisotope Physics Royal Marsden Hospital & Institute of Cancer Research Sutton UK CGPM 2018 glenn.flux@icr.ac.uk Overview
More informationPreclinical imaging and therapy. Marion de Jong
Preclinical imaging and therapy Marion de Jong Content Introduction Preclinical Imaging Preclinical Therapy to raise awareness about problems related to translation of animal studies Radiopharmaceuticals
More informationGa68 Imaging. Roland HUSTINX Division of Nuclear Medicine and Oncologic Imaging Centre Hospitalier Universitaire de Liège Belgium
Ga68 Imaging Roland HUSTINX Division of Nuclear Medicine and Oncologic Imaging Centre Hospitalier Universitaire de Liège Belgium 68 Ga Produced by a 68 Ge/ 68 Ga generator Decays by positron emission
More informationQuantitative Theranostics in Nuclear Medicine
Quantitative Theranostics in Nuclear Medicine M. Lassmann Klinik und Poliklinik für Nuklearmedizin Direktor: Prof. Dr. A. Buck Contents What is Theranostics? Potential Targets Basic Principles of Quantitative
More informationPET/CT Value: Rocky Mountain Cancer Centers
PET/CT Value: Rocky Mountain Cancer Centers Glenn Balasky Executive Director Rocky Mountain Cancer Centers glenn.balasky@usoncology.com CANM/CAMRT Joint Conference March 22, 2018 Vancouver, British Columbia
More informationTheranostics in Nuclear Medicine
Theranostics in Nuclear Medicine Patrick FLAMEN, MD, PhD Head Nuclear Medicine Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) n Theranostics in Nuclear Medicine n A form of (nuclear) diagnostic
More informationAustin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate)
Austin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate) Overview Ga-68 dotatate binds to somatostatin receptors, with highest affinity for subtype 2 receptors (sstr2). It binds to cells that express
More informationPeptide Receptor Radionuclide Therapy (PRRT) of NET
Peptide Receptor Radionuclide Therapy (PRRT) of NET Dr. Tuba Kendi Associate Prof of Radiology, Mayo Clinic, Rochester, MN 2014 MFMER slide-1 Relevant Financial Relationship(s) None Off Label Usage None
More informationLu-DOTATATE PRRT dosimetry:
177 Lu-DOTATATE PRRT dosimetry: From theory to practice Silvano Gnesin Medical Physics department Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland Gwennaëlle Marin Medical
More informationNeuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy
Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy Lawrence Saperstein, M.D. Assistant Professor of Radiology and Biomedical Imaging Chief, Nuclear
More informationNet Cancer Day Webinar
Net Cancer Day Webinar The webinar will start shortly Please make sure to dial in using the numbers provided or in the upper right hand side of the screen select Switch to Interactive Meeting to enable
More informationPeptide Receptor Radionuclide Therapy using 177 Lu octreotate
Peptide Receptor Radionuclide Therapy using 177 Lu octreotate BLR Kam, Erasmus Medical Centre, Rotterdam DJ Kwekkeboom, Erasmus Medical Centre, Rotterdam Legal aspects As 177 Lu-[DOTA 0 -Tyr 3 ]octreotate
More informationIntroduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT
Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT protocols Tips Leukaemia / lymphoma: ~ 35% acute lymphoblastic
More informationDosimetry and radiobiology for Peptide Receptor Radionuclide Therapy
Dosimetry and radiobiology for Peptide Receptor Radionuclide Therapy Short-ranged particle emitters for targeted radionuclide therapy require specific dosimetry and radiobiology Mark Konijnenberg Melodi
More informationF NaF PET/CT in the Evaluation of Skeletal Malignancy
F NaF PET/CT in the Evaluation of Skeletal Malignancy Andrei Iagaru, MD September 26, 2013 School of of Medicine Ø Introduction Ø F NaF PET/CT in Primary Bone Cancers Ø F NaF PET/CT in Bone Metastases
More informationRadioiodinated choline analogues as theranostics for cancer
Radioiodinated choline analogues as theranostics for cancer Milos Petrik, Pavel Svec, Martin Hruby, Jan Kucka, Ondrej Sedlacek, Zbynek Novy, Marian Hajduch Cancer cancer is the second leading cause of
More informationFacilitating Lu 177 Personalized Dosimetry for Neuroendocrine Tumours CANM 2017
Facilitating Lu 177 Personalized Dosimetry for Neuroendocrine Tumours CANM 2017 CANM ANNUAL SCIENTIFIC MEETING APRIL 20-23, 2017 TORONTO, ONTARIO I do not have a financial interest, arrangement or affiliation
More informationThe PET-NET Study 2016 CNETS Grant Award
The PET-NET Study 2016 CNETS Grant Award CANM Meeting April 21, 2017 Hagen Kennecke, MD, MHA, FRCPC Medical Oncology, BC Cancer Agency Associate Professor, University of British Columbia Raja Ampat, Indonesia
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies 2016 DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future events.
More informationLutetium-177 PSMA (LuPSMA) Theranostic Phase II trial: Efficacy, safety and QoL in patients
Lutetium-177 PSMA (LuPSMA) Theranostic Phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA M. S. Hofman, S. Sandhu, P. Eu, P. Jackson, T. Akhurst,
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationIndividualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy)
Individualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy) FMU/ICRP workshop 2017 Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK ICRP Task Group 101
More informationObjective. Assessment Question. I. Theranostics II. Classic Theranostic Agent
Up and Coming Research Radiopharmaceuticals Dao Le, Pharm.D, BCNP Director, Nuclear Medicine, Radiopharmacy University of Texas MD Anderson Cancer Center Objective I. Theranostics II. Classic Theranostic
More informationFirst AUBMC Theranostics Conference: See What You Treat
The Division of Nuclear Medicine, PET/CT and Cyclotron Facilities, Department of Diagnostic Radiology, AUBMC presents the First AUBMC Theranostics Conference: See What You Treat Endorsed by the International
More informationPROGRAMME OVERVIEW Saturday, October 13, 2018
Saturday, October 13, 2018 Plenary Hall Meeting Room 26 Hall 1 Hall 2 Hall 3 Hall X Hall Y Hall 28 - - - - - - - - - - Advisory Council Meeting Delegates Assembly 1 Radiopharmacy/ Drug Development Trial
More informationRodney J Hicks, MD, FRACP, FAAHMS, the Peter MaCallum Cancer Centre, Melbourne, Australia
Journal of Nuclear Medicine, published on October 6, 2016 as doi:10.2967/jnumed.116.182188 Citius, Altius, Fortius An Olympian dream for Theranostics Rodney J Hicks, MD, FRACP, FAAHMS, the Peter MaCallum
More informationSpecialised Services Policy CP66: 68-gallium DOTA- peptide scanning for the Management of Neuroendocrine Tumours (NETs)
Specialised Services Policy CP66: Management of Neuroendocrine Tumours (NETs) Document Author: Assistant Planner for Cancer and Blood Executive Lead: Director of Quality and Nursing Approved by: Management
More informationLu 177-Dotatate (Lutathera) Therapy Information
Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker CEO Jefferies Healthcare Conference June 8, 2017 DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future
More informationIART and EBRT, an innovative approach
External beam radiotherapy and nuclear medicine therapy: which kind of integration? Mahila Ferrari mahila.ferrari ferrari@ieo.it A different NM and RT integration... Radionuclide therapy combined to EBRT
More informationCase Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT
Case Report 8-YEAR SURVIVAL WITH A METASTATIC THYMIC NEUROENDOCRINE TUMOR: EMPHASIS ON REDEFINING TREATMENT OBJECTIVES USING PERSONALIZED PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 177 Lu- AND 90 Y-LABELED
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationJoint ICTP-IAEA Advanced School on Internal Dosimetry. Trieste, April 2010
Joint ICTP-IAEA Advanced School on Internal Dosimetry Trieste, 12-16 April 2010 Dosimetry in PRRT: what for Dosimetry has the purpose to address %&!"# '!&!"#!(%)* $ *!$+ Most Used Radiopeptides for PRRT
More informationCANM ACMN Annual Meeting April
117 Lu-DOTATATE & 68 Ga-DOTATATE A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of 177 Lu- DOTATATE Treatment, with individualized dosimetry, in Patients with 68 Ga-DOTATATE PET
More informationIn Vivo Measurement and Characterization of a Novel Formulation of [ 177 Lu]-DOTA-Octreotate
In Vivo Measurement and Characterization of a Novel Formulation of [ 177 Lu]-DOTA-Octreotate Dale L Bailey 1,*, Thomas M Hennessy 2, Kathy P Willowson 3, E Courtney Henry 3, David LH Chan 1, Alireza Aslani
More informationDosimetry in Nuclear Medicine Therapies
Dosimetry in uclear Therapies F. Forrer Institut of uclear University ospital Basel uclear Therapies Radioiodine Phosphonates Metabolites (e.g. 131 I-mIBG) Radiopeptides Radioimmunotherapy Radiosynoviothesis
More informationOncology Program. Chlorotoxin Technology Platform. Corporate Partnering Opportunities
TransMolecular, Inc. A Neuroscience Biotechnology Company Oncology Program Chlorotoxin Technology Platform Corporate Partnering Opportunities Background TransMolecular, Inc. (TMI) is a neuroscience biotechnology
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
PET Scanning: Oncologic Applications Page 1 of 88 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Positron Emission Tomography (PET) Scanning: Oncologic Applications
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationNuclear Medicine: Basics to therapy
Nuclear Medicine: Basics to therapy RCP Medical careers day Dr Sabina Dizdarevic MD MSc PhD FRCP Dr Deena Neriman MBBS FRCR Ms Charlotte Weston CEO BNMS On behalf of the British Nuclear Medicine Society
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationNuclear Medicine in the Diabetic Foot
26.11.2015, Uniklinik Balgrist Nuclear Medicine in the Diabetic Foot Martin Hüllner Nuklearmedizin und Neuroradiologie, USZ / UZH Outline A. Imaging modalities brief technical overview B. Nuclear medicine
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationRadionuclide Therapy: History, Present and Future Promise. History of Radionuclide (RN) Therapy. History of RN Therapy 8/2/2017
Radionuclide Therapy: History, Present and Future Promise Bennett S. Greenspan, MD, MS Professor, Dept. of Radiology, MCG / AU President, SNMMI AAPM Annual Meeting, Denver, CO History Symposium 8/02/2017
More informationInternational Course on THERANOSTICS AND MOLECULAR RADIOTHERAPY
International Course on THERANOSTICS AND MOLECULAR RADIOTHERAPY A Joint Initiative of IAEA BELNUC - JULES BORDET INSTITUTE OCTOBER 2-6, 2017 Venue: Auditorium Tagnon Jules Bordet Institute Boulevard de
More informationNew Horizons in radionuclide therapy. John Buscombe Royal Free Hospital
New Horizons in radionuclide therapy John Buscombe Royal Free Hospital Date for you diary Interested in Radionuclide imaging and therapy using antibodies and peptides IRIST 2008 Krakow Poland 18-21 June
More informationPET Guidance of Therapy for BNCT and in vivo B-10 imaging
INFN LNL Legnaro 17-19 Novembre 2009 Principles of Positron Emission Tomography and Radiopharmaceuticals PET Guidance of Therapy for BNCT and in vivo B-10 imaging Luca Menichetti, Ph.D C.N.R. Institute
More informationRonald C. Walker, MD, Prof of Radiology Vanderbilt University Medical Center Nashville, TN. Ga-DOTATATE PET/CT imaging Initial Vanderbilt experience
Ronald C. Walker, MD, Prof of Radiology Vanderbilt University Medical Center Nashville, TN 68 Ga-DOTATATE PET/CT imaging Initial Vanderbilt experience Disclosures: No financial disclosures or conflicts
More informationCURRENT STATUS AND POTENTIAL OF ALPHA-EMITTING RADIOPHARMACEUTICALS
CURRENT STATUS AND POTENTIAL OF ALPHA-EMITTING RADIOPHARMACEUTICALS Chaitanya Divgi, MD crdivgi@gmail.com NO DISCLOSURES Objectives Aware of the types of radionuclides with therapeutic potential. Familiar
More informationCowen Annual Healthcare Conference. March 2018
Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More information12th Congress of the World Federation of Nuclear Medicine and Biology April 2018 TRACK: ONCOLOGY Melbourne Convention and Exhibition Centre
12th Congress of the World Federation of Nuclear Medicine and Biology 20-24 April 2018 TRACK: ONCOLOGY Melbourne Convention and Exhibition Centre Saturday 21 April 2018 30 Jan 18 10:30-12:00 ONCOLOGY 1
More informationQuantifying Y-90 PET. The Challenges Associated With the QUEST Study. Michael Tapner Research & Development Project Manager Sirtex
Quantifying Y-90 PET. The Challenges Associated With the QUEST Study Michael Tapner Research & Development Project Manager Sirtex Internal Dosimetry with 90 Y Resin Microspheres: QUEST COUNT MAP ACTIVITY
More informationThe Use of PET Scanning in Urologic Oncology
The Use of PET Scanning in Urologic Oncology Dr Nicholas C. Buchan Uro-oncology Fellow 1 2 Aims To understand the basic concepts underlying PET scanning. Understand the emerging role of PET Scanning for
More informationRadionuclides in Medical Imaging. Danielle Wilson
Radionuclides in Medical Imaging Danielle Wilson Outline Definitions History and development Radionuclide applications & techniques in imaging Conclusion Definition #1 : Radionuclide An unstable nucleus
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationOTHER NON-CARDIAC USES OF Tc-99m CARDIAC AGENTS Tc-99m Sestamibi for parathyroid imaging, breast tumor imaging, and imaging of other malignant tumors.
DEFINITION OF CARDIAC RADIOPHARMACEUTICAL: A radioactive drug which, when administered for purpose of diagnosis of heart disease, typically elicits no physiological response from the patient. Even though
More informationASX ANNOUNCEMENT CELLMID CEO PRESENTS AT "BROKERS MEET BIOTECH
ASX ANNOUNCEMENT CELLMID CEO PRESENTS AT "BROKERS MEET BIOTECH SYDNEY, Wednesday, 18 September 2013: Cellmid Limited (ASX: CDY) provides the following shareholder update, which will be presented at the
More informationA New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy
RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi
More informationPRESENTATION TO INVESTORS. I attach a PowerPoint presentation as presented by Biotron Limited's CEO, Dr Michelle Miller, to investors today.
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 11 November 2010 The Manager Companies ASX Limited
More informationSomatostatin receptor agonists and antagonists Melpomeni Fani
Somatostatin receptor agonists and antagonists Melpomeni Fani Clinic of Radiology and Nuclear Medicine University of Basel Hospital, Switzerland Somatostatin and somatostatin receptors Human Somatostatin
More informationREDECTANE Preliminary data of the Phase III trial 30 November 2009
REDECTANE Preliminary data of the Phase III trial 30 November 2009 Forward looking statements This communication contains certain forward-looking statements, relating to the Company s business, which can
More informationDr. Sandip Basu Radiation Medicine Center (BARC) Tata Memorial Centre Annexe, Parel, Mumbai
Newer Radionuclide Therapies Dr. Sandip Basu Radiation Medicine Center (BARC) Tata Memorial Centre Annexe, Parel, Mumbai NICSTAR-2018 5 th -7 th March, 2018 A. Receptor over-expression in Tumors as Target:
More informationOption D: Medicinal Chemistry
Option D: Medicinal Chemistry Basics - unstable radioactive nuclei emit radiation in the form of smaller particles alpha, beta, positron, proton, neutron, & gamma are all used in nuclear medicine unstable
More informationChapter 10. Summary, conclusions and future perspectives
Chapter 10 Summary, conclusions and future perspectives 10.1 SUMMARY In this thesis, a new tumor imaging tracer in nuclear medicine is studied. This 123 tracer, L-3-[ I]Iodo-alpha-methyl-tyrosine (IMT),
More informationErasmus Experience. Lu-DOTA-octreotate PRRT
Erasmus Experience 177 Lu-DOTA-octreotate PRRT Mark Konijnenberg Erasmus MC, Rotterdam, Netherlands METRO/MRT meeting 2015, NPL, Teddington Leading questions? 1. For which MRT procedure dosimetry is used?
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationBORDET DEPARTMENT RADIATION ONCOLOGY
BORDET DEPARTMENT RADIATION ONCOLOGY The Radiation Oncology Department has been providing patients with high quality, tailored radiation oncology care for the last 60 years in a multidisciplinary setting
More informationProstate Cancer Panel. June 2018
Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash
More informationMolecular Imaging of Bone Metastasis Hojjat Ahmadzadehfar
Molecular Imaging of Bone Metastasis Hojjat Ahmadzadehfar Seite 1 Bone metastases Different tumors % 80 70 68% 73% 60 50 40 40% 35% 42% 36% 30 20 10 0 5% prostate bladder renal breast thyroid lung GI urological
More informationPrinciples of nuclear metabolic imaging. Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium
Principles of nuclear metabolic imaging Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium I. Molecular imaging probes A. Introduction - Chemical disturbances will precede anatomical abnormalities
More informationSurgical Therapy of GEP-NET: An Overview
Surgical Therapy of GEP-NET: An Overview Pierce K.H Chow MBBS, MMed, FRCSE, FAMS, PhD Professor, Duke-NUS Graduate School of Medicine Senior Consultant Surgeon, Singapore General Hospital Visiting Senior
More informationRadiopharmacy. Prof. Dr. Çetin ÖNSEL. CTF Nükleer Tıp Anabilim Dalı
Prof. Dr. Çetin ÖNSEL CTF Nükleer Tıp Anabilim Dalı What is Nuclear Medicine? Nuclear Medicine is the branch of medicine concerned with the use of radionuclides in the study and the diagnosis of diseases.
More informationPET/CT imaging and RIT of prostate cancer. Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark
PET/CT imaging and RIT of prostate cancer Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark Prostate cancer Prostate cancer is the most common malignancy in men Imaging
More informationPET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
More informationORYX Translational Medicine. Dr. Bernard Huber/ CEO
ORYX Translational Medicine Dr. Bernard Huber/ CEO ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany
More informationRadionuclide & Radiopharmaceuticals
Radionuclide & Radiopharmaceuticals 1. Generator & Reactors 2. Cyclotrons & PET tracer 3. Quality control 4. Renal 5. GIT 6. CNS & Psychiatrics 7. Tumor Diagnosis & Treatment 8. Bones & joints 9. Thyroid
More informationThe Drug Development Paradigm in Oncology: Role of Imaging Hedvig Hricak MSKCC
The Drug Development Paradigm in Oncology: Role of Imaging Hedvig Hricak MSKCC Precision Medicine: Imaging in Clinical Trials and Drug Development* Critical elements: Patient Selection, Dose Finding &
More informationIsotopes in Functional Cancer Imaging
Seeing and Believing: i Medical Isotopes in Functional Cancer Imaging François Bénard, MD, FRCPC BCCancer Cancer Agency and University of British Columbia Nuclear Medicine 101 A radioactive atom is produced
More informationSpecial Considerations for Tracers Based on Proteins or Protein Fragments
Special Considerations for Tracers Based on Proteins or Protein Fragments 10 June, 2017 Serge K. Lyashchenko, Pharm.D. Assistant Attending, Memorial Hospital, Memorial Sloan Kettering Cancer Center Assistant
More informationMolecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin
Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate
More informationUnderstanding Biological Activity to Inform Drug Development
National Cancer Policy Forum Understanding Biological Activity to Inform Drug Development December 12, 2016 Wolfgang Weber Molecular Imaging and Therapy Service Department of Radiology RECIST Response
More informationFMU-ICRP Workshop on Radiological Protection in Medicine Current Status in Radionuclide Therapy Tuesday, October 3, 2017 Makoto Hosono, MD PhD Kindai
FMU-ICRP Workshop on Radiological Protection in Medicine Current Status in Radionuclide Therapy Tuesday, October 3, 2017 Makoto Hosono, MD PhD Kindai University Faculty of Medicine, Osaka, Japan Current
More informationPostgraduate Diploma in Health Sciences in Medical Imaging (Nuclear Medicine Pathway)
Postgraduate Diploma in Health Sciences in Medical Imaging (Nuclear Medicine Pathway) Introduction The Nuclear Medicine pathway of the Postgraduate Diploma in Health Sciences (Medical Imaging) provides
More informationIpsen Oddo BHF Forum January 12, 2018
Ipsen Oddo BHF Forum 2018 January 12, 2018 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationDr. Bernard Huber CEO. Bio-Europe
Dr. Bernard Huber CEO Bio-Europe 2015 1 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany ORYX bridges
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationPET/CT in oncology. Positron emission tomography
Clinical Medicine 2012, Vol 12, No 4: 368 72 PET/CT in oncology Fahim-Ul-Hassan, SpR Nuclear Medicine, Guy s Hospital, London; Gary J Cook, professor of Clinical PET, KCL Division of Imaging Sciences &
More informationPET/MR:Techniques, Indications and Applications
PET/MR:Techniques, Indications and Applications Franz Wolfgang Hirsch Professor and Head of the Department of Pediatric Radiology University Hospital Leipzig / Germany Children s Hospital University Leipzig
More informationThird announcement. Joint FMU-ICRP Workshop on Radiological Protection in Medicine. Tuesday, October 3, 2017
ICRP ref: 4852-9144-9932 Third announcement Joint FMU-ICRP Workshop on Radiological Protection in Medicine Tuesday, October 3, 2017 Organised by Fukushima Medical University (FMU) and the International
More informationDendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity
Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity Melbourne, Australia; Wednesday 11 September 2013: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved
More informationChapter 19: Radionuclide Therapy
Chapter 19: Radionuclide Therapy Slide set of 40 slides based on the chapter authored by G. Flux and Y. Du of the publication (ISBN 978 92 0 143810 2): Nuclear Medicine Physics: A Handbook for Teachers
More informationPET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany
PET-MRI in malignant bone tumours Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to PET/MRI General considerations Bone metastases Primary bone tumours
More information